KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $2.3 million.

  • Supernus Pharmaceuticals' Other Non Operating Income fell 4443.63% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.2 million, marking a year-over-year increase of 2265.95%. This contributed to the annual value of $16.2 million for FY2024, which is 5501.77% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Other Non Operating Income stood at $2.3 million for Q3 2025, which was down 4443.63% from $4.5 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Other Non Operating Income high stood at $14.7 million for Q1 2022, and its period low was -$21.5 million during Q4 2021.
  • Its 5-year average for Other Non Operating Income is $2.5 million, with a median of $2.8 million in 2022.
  • In the last 5 years, Supernus Pharmaceuticals' Other Non Operating Income plummeted by 87162.31% in 2021 and then soared by 28557.19% in 2022.
  • Supernus Pharmaceuticals' Other Non Operating Income (Quarter) stood at -$21.5 million in 2021, then soared by 111.14% to $2.4 million in 2022, then dropped by 17.25% to $2.0 million in 2023, then soared by 150.6% to $5.0 million in 2024, then plummeted by 54.25% to $2.3 million in 2025.
  • Its Other Non Operating Income was $2.3 million in Q3 2025, compared to $4.5 million in Q2 2025 and $4.4 million in Q1 2025.